anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

221,941-222,000 of 319,975

filter-aware
54
Includes footnotes regarding Uni-Select acquisition and Ukraine/Russia conflict impacts.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
55
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
56
Contains footnotes regarding Uni-Select acquisition and Ukraine/Russia conflict impacts.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
57
This is a standard financial disclosure slide found in investor presentations to justify non-GAAP adjustments.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
58
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
59
Includes footnote regarding Uni-Select acquisition.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
60
Includes a footnote regarding the exclusion of gains from the sale of businesses in FCF conversion.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
61
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
62
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
01
Slide 1
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
02
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style layout to represent drug development stages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a visual comparison of population growth to frame the problem of age-related cancer.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
09
This slide serves as a transition or key message reinforcement.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
10
The slide illustrates the interaction between THIO (telomere targeting) and standard checkpoint inhibitor therapies.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
11
This slide serves as a validation/traction point by highlighting a partnership with a major pharmaceutical company.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo across efficacy, safety, and administration metrics.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
15
The slide compares the safety profile of THIO against standard of care (SOC) chemotherapy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
16
DCR stands for Disease Control Rate. The table compares historical benchmarks (Standard of Care) against the company's clinical trial results (THIO-101).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
17
Data presented in a table format with footnotes explaining the methodology for DCR calculation.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
18
DCR = Disease Control Rate. Data shows high efficacy across all tested dose levels.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
19
Clinical trial data visualization showing patient-level outcomes over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
22
The slide provides visual and quantitative evidence of the drug's mechanism of action (MOA) by showing the increase of TIFs over 72 hours.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
Includes two line charts showing tumor volume reduction and rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
25
The slide compares clinical trial data for three different treatment regimens in CRC patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
26
The table compares historical standard of care data against planned THIO-102 trial outcomes.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
27
The table compares an existing standard of care (Zepzelca) against the company's planned trial (THIO-102).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC models.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
29
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
32
The slide outlines both regulatory exclusivity (NCE) and patent protection (issued/pending) to establish a competitive moat.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
33
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
34
The slide includes specific details on options, warrants, and insider ownership percentages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
35
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
36
The chart compares the combined market size of major CPIs ($42B) against Libtayo ($0.5B) to illustrate the growth potential.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pareto Focus1 hit
37
The slide uses a table-like layout to associate logos with market cap figures, followed by specific acquisition deal context.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pareto Focus1 hit
38
The slide uses a growth curve background to imply value accumulation over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Slide 1
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
02
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
03
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
04
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Problem1 hit
05
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Problem1 hit
06
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a numbered list structure to define the core pillars of the investment strategy.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Solution1 hit
08
The chart uses a dual-axis approach to show both per-share metrics and NAV growth over time.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
09
LMM stands for Lower Middle Market.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
10
LMM stands for Lower Middle Market.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Market Size1 hit
11
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
12
Main Street Capital | Investor Presentation Deck | 49 slidesMain Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit